Profile · INSIDERData sourcesSEC FORM 43m ago
HOUSE PTR3m ago
SEC 13F2m ago
ROBINHOOD CHAIN2m ago
Public companyKeros Therapeutics, Inc.
KROSCIK 0001664710
Price$9.45
1 year-39.2%
Disclosed transactions14
Buys / sells0 / 7
Max Insider Score36
Connections with evidence7
KROS · disclosed activity on price
| Score | Actor | Security | Side | Value | Executed | Disclosed | Lag | Source | Evidence |
|---|
| 36 | CECho EstherChief Legal Officer | KROSKeros Therapeutics, Inc. Open-market sale | SELL | $46K 4,485 sh | Aug 18, 2026 | Aug 20, 2026 |
| 36 | TATanini AnnitaCorp. Controller & VP, Finance | KROSKeros Therapeutics, Inc. Open-market sale | SELL | $13K 1,224 sh | Aug 18, 2026 | Aug 20, 2026 traded Aug 18, 2026 | +2d | SEC FORM 4 | |
| 36 | LRLerner Lorena RaquelChief Scientific Officer | KROSKeros Therapeutics, Inc. Open-market sale | SELL | $37K 3,568 sh | Aug 18, 2026 | Aug 20, 2026 traded Aug 18, 2026 | +2d | SEC FORM 4 | |
| 16 | NWNewton Charles W.Director | KROSKeros Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $5,675 551 sh | Aug 18, 2026 | Aug 20, 2026 traded Aug 18, 2026 | +2d | SEC FORM 4 | |
| 5 | NWNewton Charles W.Director | KROSKeros Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $5,522 550 sh | Jun 11, 2026 | Jun 15, 2026 traded Jun 11, 2026 | +4d | SEC FORM 4 | |
| 13 | SJSeehra JasbirDirector, CHIEF EXECUTIVE OFFICER | KROSKeros Therapeutics, Inc. Option exercise | M | $17K 55.0K sh | Apr 2, 2026 | Apr 6, 2026 traded Apr 2, 2026 | +4d | SEC FORM 4 | |
| 17 | SJSeehra JasbirDirector, CHIEF EXECUTIVE OFFICER | KROSKeros Therapeutics, Inc. Option exercise | M | — 55.0K sh | Apr 2, 2026 | Apr 6, 2026 traded Apr 2, 2026 | +4d | SEC FORM 4 | |
| 5 | LRLerner Lorena RaquelChief Scientific Officer | KROSKeros Therapeutics, Inc. Grant or award | A | — 75.0K sh | Feb 24, 2026 | Feb 26, 2026 traded Feb 24, 2026 | +2d | SEC FORM 4 | |
| 5 | CECho EstherChief Legal Officer | KROSKeros Therapeutics, Inc. Grant or award | A | — 80.0K sh | Feb 24, 2026 | Feb 26, 2026 traded Feb 24, 2026 | +2d | SEC FORM 4 | |
| 33 | CECho EstherSVP, General Counsel | KROSKeros Therapeutics, Inc. Open-market sale | SELL | $78K 4,745 sh | Feb 18, 2026 | Feb 20, 2026 traded Feb 18, 2026 | +2d | SEC FORM 4 | |
| 33 | LRLerner Lorena RaquelChief Science Officer | KROSKeros Therapeutics, Inc. Open-market sale | SELL | $63K 3,873 sh | Feb 18, 2026 | Feb 20, 2026 traded Feb 18, 2026 | +2d | SEC FORM 4 | |
| 9 | SJSeehra JasbirDirector, CHIEF EXECUTIVE OFFICER | KROSKeros Therapeutics, Inc. Grant or award | A | — 62.5K sh | Jan 7, 2026 | Jan 9, 2026 traded Jan 7, 2026 | +2d | SEC FORM 4 | |
| 28 | | KROSKeros Therapeutics, Inc. Disposition to issuer | D | $2.32M 130.5K sh | Nov 21, 2025 | Dec 18, 2025 traded Nov 21, 2025 | +27d | SEC FORM 4 | |
| 28 | | KROSKeros Therapeutics, Inc. Disposition to issuer | D | $3.40M 191.5K sh | Nov 21, 2025 | Dec 18, 2025 traded Nov 21, 2025 | +27d | SEC FORM 4 | |
Chief Science Officer · Feb 20, 2026